15,500 Shares in Edwards Lifesciences Corporation $EW Purchased by Versor Investments LP

Key Points

• Versor Investments LP has acquired 15,500 shares of Edwards Lifesciences Corporation, valued at approximately $1,123,000, reflecting increasing institutional interest in the company.
• Multiple analysts have raised their price targets for Edwards Lifesciences, with Barclays increasing its target from $90.00 to $95.00, indicating overall positive sentiment about the stock's performance.
• Edwards Lifesciences reported earnings of $0.67 per share, surpassing analyst expectations and showing an 11.9% year-over-year revenue increase, with 52-week high and low prices of $83.00 and $64.00 respectively.

Versor Investments LP bought a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 15,500 shares of the medical research company's stock, valued at approximately $1,123,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Prosperity Consulting Group LLC boosted its position in shares of Edwards Lifesciences by 3.6% during the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock valued at $289,000 after purchasing an additional 134 shares in the last quarter. Arlington Trust Co LLC increased its holdings in shares of Edwards Lifesciences by 1.2% in the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock valued at $804,000 after purchasing an additional 135 shares during the period. Valeo Financial Advisors LLC increased its holdings in shares of Edwards Lifesciences by 2.8% in the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock valued at $372,000 after purchasing an additional 142 shares during the period. Versant Capital Management Inc increased its holdings in shares of Edwards Lifesciences by 9.3% in the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock valued at $123,000 after purchasing an additional 145 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after buying an additional 145 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Wells Fargo & Company boosted their price target on Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a research note on Thursday, August 7th. Truist Financial lifted their price target on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a research report on Friday, July 25th. BTIG Research raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective on the stock in a report on Tuesday, July 29th. Daiwa America upgraded Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Finally, Robert W. Baird raised their target price on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus target price of $85.90.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $77.40, for a total transaction of $198,918.00. Following the transaction, the vice president owned 50,356 shares in the company, valued at $3,897,554.40. This represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,584 shares of company stock valued at $1,897,762 in the last three months. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Trading Up 0.7%

Shares of EW traded up $0.5950 during trading hours on Friday, reaching $81.7550. The stock had a trading volume of 2,834,998 shares, compared to its average volume of 4,517,584. The company has a market cap of $48.00 billion, a P/E ratio of 11.76, a P/E/G ratio of 3.93 and a beta of 1.08. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The firm has a 50-day moving average of $77.45 and a 200 day moving average of $74.60.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.